Endocannabinoid Deficiency and Mast Cell Brake Failure
The endocannabinoid system (ECS) acts as a global neuroimmune modulator, with 2-arachidonoylglycerol (2-AG) serving as the primary agonist at CB1 and CB2 receptors to suppress neuroinflammation, reduce mast cell degranulation, and regulate pain thresholds. This section proposes that Clinical Endocannabinoid Deficiency (CECD) in ME/CFS β evidenced by reduced 2-AG levels and CB1 receptor downregulation β removes a key brake on mast cell activation and neuroinflammatory amplification, contributing to symptom severity.
1 Endocannabinoid System Architecture
The endocannabinoid system (ECS) comprises two main G-protein-coupled receptors (CB1 and CB2), two principal endogenous ligands (anandamide and 2-arachidonoylglycerol, 2-AG), and the enzymatic machinery for their on-demand synthesis and degradation. CB1 receptors are concentrated at presynaptic terminals throughout the CNS, mediating retrograde suppression of neurotransmitter release; CB2 receptors are predominantly expressed by peripheral immune cells including mast cells, macrophages, natural killer cells and microglia where they suppress pro-inflammatory signaling. 2-AG, the more abundant ECS agonist, is synthesized from membrane diacylglycerol by diacylglycerol lipase (DAGL-\(\alpha\)/\(\beta\)) and degraded primarily by monoacylglycerol lipase (MAGL), whose pharmacological inhibition substantially elevates 2-AG tissue levels.
2 Mast Cell ECS Brake and Its Failure
Mast cell degranulation the release of histamine, tryptase, prostaglandins, leukotrienes and cytokines is normally suppressed by CB2 receptor activation via the DAGL-\(\beta\)/2-AG/CB2 signaling axis. Palmitoylethanolamide (PEA) inhibits mast cell degranulation via this pathway and is meta-analytically effective for nociceptive, neuropathic and nociplastic pain (including conditions overlapping with ME/CFS) (Artukoglu et al. 2017) (Lang-Ilievich et al. 2023). Cannabidiol (CBD) additionally suppresses IgE-mediated mast cell degranulation by inhibiting Fc\(\varepsilon\)RI downstream signaling and calcium mobilization, with effects preserved even in CB1/CB2-depleted cells, suggesting additional non-canonical mechanisms (Yang et al. 2024).
Ethan Russo proposed that fibromyalgia, migraine and irritable bowel syndrome share an underlying Clinical Endocannabinoid Deficiency (CECD): reduced anandamide/2-AG tone, impaired CB receptor signaling, and consequent loss of ECS-mediated homeostatic regulation of pain, sleep and immune function (Russo 2004). Updated evidence supports this hypothesis: CSF anandamide is statistically reduced in migraineurs, and PTSD β another post-traumatic condition with ME/CFS overlap β shows ECS hypofunction on advanced neuroimaging (Russo 2016). By analogy, ME/CFS may represent a CECD state in which mast cell CB2 signaling is insufficient, removing the primary brake on mast cell degranulation and neuroinflammatory amplification. Direct measurement of CSF anandamide and 2-AG, and CB receptor expression in immune cells, in ME/CFS patients is required to test this hypothesis. (Certainty: Low; extrapolated from fibromyalgia and PTSD evidence; no direct ME/CFS CSF endocannabinoid measurements published.)
3 Therapeutic Implications
Current ECS-targeting approaches with evidence in ME/CFS-relevant conditions include:
- Palmitoylethanolamide (PEA): Ultra-micronized PEA 600β1200mg/day; inhibits mast cell degranulation via DAGL-\(\beta\)/2-AG/CB2 pathway; effective for nociplastic pain (\(\text{SMD} = -0.59\), peak effect at 24β26 weeks) (Lang-Ilievich et al. 2023).
- Cannabidiol (CBD): Non-psychoactive; suppresses mast cell degranulation by CB1/CB2-independent mechanism; also attenuates microglial activation (Yang et al. 2024).
- Lifestyle ECS enhancement: Sleep normalization and stress reduction each tonically elevate endocannabinoid levels. In mild ME/CFS, gentle movement within the energy envelope may also contribute; in moderate-to-severe patients (see Disease Course and Prognosis for severity classification), even minimal physical activity may exceed the PEM threshold, and this intervention is not applicable β rest-based ECS support (sleep, stress reduction) takes priority.